Cholangiolocellular Carcinoma With “Ductal Plate Malformation” Pattern May Be Characterized by ARID1A Genetic Alterations

Cholangiolocellular carcinoma (CLC) is a unique subtype of primary liver carcinoma, which sometimes coexists with hepatocellular carcinoma (HCC), cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma (cHCC-CCA). “Ductal plate malformation” (DPM)-pattern of primary liver carcinoma, which resembles biliary lesions in Caroli disease and von Meyenburg complex, is sometimes associated with CLC. We examined genetic alterations of hTERT promoter (hTERT), IDH1 or 2 (IDH1/2), KRAS, ARID1A, PBRM1, ARID2, BAP1, p53 and their association with histologic features such as proportion of CLC and DPM-pattern in 77 patients with primary liver carcinoma diagnosed as cHCC-CCA or CLC. Primary liver carcinomas were histologically subdivided into 29 CLC-predominant (CLC component >80%), 31 with CLC (5% to 80%) and 17 without CLC (<5%). CLC-predominant group was characterized by older age, male-predominant and smaller tumor size. Genetic alterations were detected in hTERT (25%), ARID1A (21%), PBRM1 (20%), ARID2 (3%), BAP1 (1%), p53 (46%), KRAS (5%), and IDH1/2 (8%). ARID1A alteration was more frequent in CLC-predominant group, compared with other groups (P<0.05) and was correlated with the degree of DPM-pattern (P<0.01). Alterations of hTERT and p53 were less frequent in CLC-predominant group compared with “with CLC group” (P<0.05). hTERT mutation was less frequent in carcinomas with DPM-pattern (P<0.01). PBRM1 alteration was more frequent in CLC with focal HCC subgroup and without CLC group compared with other groups (P<0.05). CLC may be a distinct subgroup of primary liver carcinoma, which is different from cHCC-CCA, based on clinicopathologic and genetic alterations. ARID1A alterations may characterize CLC with DPM-pattern and could be a diagnostic immunohistochemical marker for small CLCs with DPM-pattern.

[1]  H. Seno,et al.  ARID1A Maintains Differentiation of Pancreatic Ductal Cells and Inhibits Development of Pancreatic Ductal Adenocarcinoma in Mice. , 2018, Gastroenterology.

[2]  Kathryn J Fowler,et al.  cHCC‐CCA: Consensus terminology for primary liver carcinomas with both hepatocytic and cholangiocytic differentation , 2018, Hepatology.

[3]  Baofeng Lian,et al.  Whole-exome mutational and transcriptional landscapes of combined hepatocellular cholangiocarcinoma and intrahepatic cholangiocarcinoma reveal molecular diversity. , 2018, Biochimica et biophysica acta. Molecular basis of disease.

[4]  M. Fassan,et al.  Genetic alterations analysis in prognostic stratified groups identified TP53 and ARID1A as poor clinical performance markers in intrahepatic cholangiocarcinoma , 2018, Scientific Reports.

[5]  G. Getz,et al.  Genomic characterization of biliary tract cancers identifies driver genes and predisposing mutations. , 2018, Journal of hepatology.

[6]  A. Luciani,et al.  Macrotrabecular‐massive hepatocellular carcinoma: A distinctive histological subtype with clinical relevance , 2018, Hepatology.

[7]  Bin Tean Teh,et al.  Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma. , 2017, Cancer discovery.

[8]  L. Wood,et al.  PBRM1 loss is a late event during the development of cholangiocarcinoma , 2017, Histopathology.

[9]  Y. Pomyen,et al.  Common Molecular Subtypes Among Asian Hepatocellular Carcinoma and Cholangiocarcinoma. , 2017, Cancer cell.

[10]  Ke Hao,et al.  Mixed hepatocellular cholangiocarcinoma tumors: Cholangiolocellular carcinoma is a distinct molecular entity. , 2017, Journal of hepatology.

[11]  D. Schadendorf,et al.  SF3B1 and BAP1 mutations in blue nevus-like melanoma , 2017, Modern Pathology.

[12]  Yasunori Sato,et al.  Mutational landscape of combined hepatocellular carcinoma and cholangiocarcinoma, and its clinicopathological significance , 2017, Histopathology.

[13]  Yasunori Sato,et al.  Loss of ARID1A Expression Presents a Novel Pathway of Carcinogenesis in Biliary Carcinomas. , 2016, American journal of clinical pathology.

[14]  Hiromi Nakamura,et al.  Genomic spectra of biliary tract cancer , 2015, Nature Genetics.

[15]  Jessica Zucman-Rossi,et al.  Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets , 2015, Nature Genetics.

[16]  Yasunori Sato,et al.  Clinicopathological significance of ‘subtypes with stem‐cell feature’ in combined hepatocellular‐cholangiocarcinoma , 2015, Liver international : official journal of the International Association for the Study of the Liver.

[17]  Keith A. Boroevich,et al.  Whole-genome mutational landscape of liver cancers displaying biliary phenotype reveals hepatitis impact and molecular diversity , 2015, Nature Communications.

[18]  G. Mills,et al.  Mutation Profiling in Cholangiocarcinoma: Prognostic and Therapeutic Implications , 2014, PloS one.

[19]  Hiromi Nakamura,et al.  Trans-ancestry mutational landscape of hepatocellular carcinoma genomes , 2014, Nature Genetics.

[20]  L. Wood,et al.  Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups , 2014, Oncotarget.

[21]  David M. Jones,et al.  New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing. , 2014, The oncologist.

[22]  Swe Swe Myint,et al.  Exome sequencing identifies distinct mutational patterns in liver fluke–related and non-infection-related bile duct cancers , 2013, Nature Genetics.

[23]  T. Pawlik,et al.  Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas , 2013, Nature Genetics.

[24]  I. Shih,et al.  Loss of ARID1A Expression Correlates With Stages of Tumor Progression in Uterine Endometrioid Carcinoma , 2013, The American journal of surgical pathology.

[25]  Masakazu Yamamoto,et al.  Intrahepatic Cholangiocarcinoma With Predominant “Ductal Plate Malformation” Pattern: A New Subtype , 2012, The American journal of surgical pathology.

[26]  Keith A. Boroevich,et al.  Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators , 2012, Nature Genetics.

[27]  P. A. Futreal,et al.  Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma , 2010, Nature.

[28]  Richard A. Moore,et al.  ARID1A mutations in endometriosis-associated ovarian carcinomas. , 2010, The New England journal of medicine.

[29]  O. Matsui,et al.  A subgroup of intrahepatic cholangiocarcinoma with an infiltrating replacement growth pattern and a resemblance to reactive proliferating bile ductules: ‘bile ductular carcinoma’ , 2007, Histopathology.

[30]  M. Matsuda,et al.  Clinicopathological study on cholangiolocellular carcinoma suggesting hepatic progenitor cell origin , 2007, Hepatology.

[31]  Y. Maehara,et al.  Histologic Characteristics and Prognostic Significance in Small Hepatocellular Carcinoma With Biliary Differentiation: Subdivision and Comparison With Ordinary Hepatocellular Carcinoma , 2007, The American journal of surgical pathology.

[32]  A. West,et al.  Nomenclature of the finer branches of the biliary tree: Canals, ductules, and ductular reactions in human livers , 2004, Hepatology.

[33]  K. Tsuneyama,et al.  Intrahepatic cholangiocarcinoma in cirrhosis presents granulocyte and granulocyte-macrophage colony-stimulating factor. , 2003, Human pathology.

[34]  K. Chayama,et al.  Incidence of primary cholangiocellular carcinoma of the liver in Japanese patients with hepatitis C virus–related cirrhosis , 2000, Cancer.

[35]  J. Hoofnagle,et al.  Classification of chronic hepatitis: Diagnosis, grading and staging , 1994, Hepatology.

[36]  P. Steiner,et al.  Cholangiolocellular carcinoma of the liver , 1959, Cancer.

[37]  M. Choi,et al.  Clinicopathologic features and prognosis of combined hepatocellular cholangiocarcinoma. , 2005, American journal of surgery.